Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 20/20 | 0.80 |
| ▸ | CXCR2 | P25025 | 20/20 | 0.80 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.80 |
| ▸ | CCR6 | P51684 | 2/20 | 0.80 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.69 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.69 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.69 |
| ▸ | CCR7 | P32248 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12263314 | 0.90 | CXCR1 (0.90) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL14905813 | 0.89 | CXCR1 (0.73) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL14894328 | 0.89 | CXCR1 (1.00) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL14894327 | 0.89 | CXCR1 (1.00) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL14905804 | 0.89 | CXCR1 (1.00) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL21297009 | 0.86 | CXCR1 (1.00) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL14894646 | 0.86 | CXCR1 (1.00) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL17004517 | 0.84 | CXCR1 (0.71) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL14894886 | 0.82 | CXCR1 (1.00) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL14895346 | 0.82 | CXCR1 (1.00) | CXCR1CXCR2CXCR3CCR6CXCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771334-B1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RES & DEV (FR) | 2015-08-19 | — | — | EP | claimed |
| EP-2771334-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | Galderma Research & Development (FR) | 2014-09-03 | — | — | EP | claimed |
| WO-2013061005-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | claimed |
| EP-2771334-B1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RES & DEV (FR) | 2015-08-19 | — | — | EP | disclosed |
| EP-2771334-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | Galderma Research & Development (FR) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013061005-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-02 | — | — | WO | disclosed |